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To determine the association between factors and adherence to immunomodulator treatment in people 
with multiple sclerosis treated in reference centers. Cross-sectional study conducted with 188 people 
who used immunomodulators in three reference centers in Ceará from March to July 2012. Adherence 
was assessed using the Moriskscale and factors were assessed using a questionnaire addressing 
socioeconomic and personal characteristics, the disease, the use of immunomodulator and educational 
activities. The determination of the association was expressed in crude and adjusted odds ratio with a 
95% confidence interval. Adherence rate was 46% and after the logistic regression model the adherence 
to immunomodulator treatment was positively associated with the following factors: age 18-38 years, 
time of diagnosis and treatment between 6 and 24 months, 0-3.5 score in the Expanded Disability Status 
Scale, perception of treatment benefits, intrinsic and extrinsic motivation, phone contact with the doctor 
and not missing the return visit. This study is important because it allowed to determine the association 
between factors and adherence to immunomodulator treatment in multiple sclerosis, contributing to 
prevention and control actions.
Uniterms: Multiple sclerosis/medication adherence. Multiple sclerosis/treatment. Immunologic factors. 
Risk factors.
INTRODUCTION
Medication adherence is essential to the effective 
treatment of many diseases, particularly the chronic ones 
(Wolf et al.; 2007; Conn et al., 2016). In people’s lives, 
such adherence can positively contribute to slow down the 
clinical progression of the disease and improve quality of 
life. In health services, it can reduce hospitalization costs 
(World Health Organization, 2003; Sokol et al., 2005).
The World Health Organization (2003) defines 
adherence to treatment as the extent to which a person’s 
behavior – taking medication, following a diet, and/or 
executing lifestyle changes - corresponds with agreed 
recommendations from a health care provider. Some studies 
show that adherence is influenced by patient’s behavior 
and beliefs such as the benefits and the importance given to 
health in addition to the type of medication administration 
and socioeconomic characteristics (Tremlett et al., 2008; 
Treadaway et al., 2009; Devonshire et al., 2011; López-
Méndez et al., 2013).
Multiple sclerosis (MS) is a chronic, progressive 
and disabling inflammatory disorder of the central 
nervous system (Rio, Comabella, Montalban, 2011) and 
its treatment includes the continuous use of medications, 
especially immunomodulators (IM). Given that, adherence 
to treatment is essential to maximize the benefits of the 
therapy (Devonshire et al., 2011).
In Brazil, the treatment for MS is provided by the 
Ministry of Health through the National Health System, 
also known as the Unified Health System (Sistema 
Único de Saúde – SUS). Patients must be treated in 
specialized services with an adequate infrastructure for 
their monitoring and the fist-line treatment includes the 
glatiramer acetate and beta interferon (Brasil, 2015). In 
the state of Ceará, Northeastern Brazil, patients are treated 
in three Reference Centers linked to high complexity 
hospitals where they can receive the diagnosis and be 
monitored. 
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This article aims to determine the association 
between factors and the adherence to immunomodulator 
treatment in people with multiple sclerosis treated in 
reference centers.
METHOD
Type of study
Cross-sectional study conducted with people with 
multiple sclerosis treated in Reference Centers in the state 
of Ceará, Northeastern Brazil, from April to July 2012. 
Research locale
The three Reference Centers for patients with 
multiple sclerosis of the state of Ceará are run by the 
SUS and present a proper structure for the diagnosis and 
treatment of the disease. Two centers are located in the city 
of Fortaleza, capital of Ceará. One center belongs to a State 
Hospital and the other is part of the Federal University 
of Ceará (Universidade Federal do Ceará – UFC). Both 
centers receive MS patients from all over the state. The 
third center is located in the state’s countryside, about 200 
km from Fortaleza, and provides care to patients from 
Northern Ceará. The centers receive an average of 140 
patients per month. 
Study population
The total population diagnosed with multiple 
sclerosis or clinically isolated syndrome (CIS) and 
treated with one of the injectable immunomodulators 
(intramuscular interferon beta-1a, subcutaneous interferon 
beta-1a, interferon beta-1b or glatiramer acetate) included 
228 people. All these immunomodulators were dispensed 
free of charge in the pharmacies of the three Reference 
Centers. 
Inclusion criteria were: patients aged over 18 
years old diagnosed with MS or CIS treated in the 
aforementioned centers with one of the injectable 
immunomodulators for at least six months. Exclusion 
criteria were: patients treated with other medications rather 
than immunomodulators. 
Variables of the study
The dependent variable was the adherence to 
treatment with immunomodulators assessed by the 
Morisky Medication Adherence Scale (MMAS-8) 
(Morisky et al., 2008). The items regarding the inadequate 
use of medication were: forgetting to take the medication; 
stopping taking the medication on his/her own when 
feeling better; stopping taking the medication when feeling 
worse and problems related to the complexity of the 
therapy - seven questions should be answered negatively 
and one should be answered positively.
The degree of adherence to the treatment was 
determined by the scoring of the sum of all correct 
answers. Patients who scored eight in the MMAS-8 were 
considered adherent (Morisky et al., 2008).
Independent variables were: socioeconomic 
characteristics (marital status, education, monthly 
household income, paid job, economic status); personal 
characteristics (gender, color, age, intrinsic and extrinsic 
motivation); aspects related to the disease (time of 
diagnosis assessed through medical records and rate of 
disease progression measured through the Expanded 
Disability Status Scale – EDSS); aspects related to the use 
of immunomodulators (length of treatment, difficulties 
to obtain and administer the IM, perception of the 
benefits of the use of the IM, who administers the IM, 
lifestyle changes, side effects caused by the medication); 
educational actions performed in the health care services 
(information about the disease and its treatment and 
on how to contact the doctor, and return to scheduled 
consultations). These variables were collected through 
self-reported information.
Economic status: it was measured according to the 
Brazilian Economic Classification Criteria established 
by the Brazilian Association of Enterprises and Research 
(Associação Brasileira de Empresas e Pesquisa) that 
takes into account the educational level and the number of 
consumer goods in the household (Associação Brasileira 
de Empresas de Pesquisa, 2012). 
Intrinsic motivation refers to the patient’s 
opportunity to control  the disease (“avoid” i ts 
progression), his/her hope to avoid episodes and get 
better, and the perception of improvement of the 
symptoms. Extrinsic motivation refers to an external 
influence on the use of the medication caused by the 
family, health care professionals and friends. 
Data collection
Data were collected by applying a formulary 
during directive interviews. The form had 155 questions 
distributed in six parts. The interview was conducted on 
the day of consultations in the Reference Centers. The 
interviewees signed the free informed consent form. 
Data collection occurred simultaneously in the three 
centers. 
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Statistical method
Data were organized in the SPSS (SPSS Inc., 
Chicago, USA), version 16.0 and analyzed by the 
software STATA (STATA Corp LP, College Station, TX 
77845, USA), version 11.0. The exploratory analyses of 
quantitative variables were performed using measures 
of central tendency (mean and median) and dispersion 
(standard deviation) to test for normality of proportions. 
The categorical variables were presented as proportions.
The chi-square test (χ2) was used in the construction 
of the logistic regression model in which the dependent 
variable was the adherence to medication treatment 
and independent variables were the socioeconomic 
characteristics and characteristics of the disease, - 
treatment and the ones related to the patient and the 
health care professional. Statistical significance was set 
at p<0.05. The selection of variables for the construction 
of the multivariate logistic regression model was based on 
the automatic selection method (stepwise). The strength 
of association between the dependent variable and the 
independent variables was expressed by the value of crude 
and adjusted Odds Ratio (OR) with a 95% Confidence 
Interval (CI). 
Ethical Aspect
The study followed all the guidelines of -resolution 
466/12 established by the National Health Council and 
was approved by the Ethics Research Committee of the 
University of Fortaleza under Opinion No. 445/2012.
RESULTS
Participants were 188 people with multiple sclerosis 
treated in the three Reference Centers of Ceará, which 
corresponded to 84.1% of the patients registered in the 
centers; there was a loss of 15.9% (30) of people who did 
not participate in the study because they had been using 
the medications for less than six months and also used 
other medications. Most of the 188 people with multiple 
sclerosis undergoing treatment were: under 38 years old 
(45.8%), with a mean age of 38.6 years; women (75.5%); 
white (84.0%); had a higher education degree (52.7%); 
and were unemployed (56.9%). Almost half of the patients 
(45.7%) were married; 59.0% were classified as belonging 
to income class A/B with an average household income of 
R$ 2,214.89 per month (Table I). 
Most patients had an Expanded Disability Status 
Scale score (EDSS score) below 3.5 (65.4%) and the 
average time of diagnosis and treatment was 73.9 and 
64.6 months, respectively. Most patients feel intrinsically 
motivated to adhere to the treatment (77.1%) due to: 
believing that immunomodulator medication avoids 
the disease progression (77.3%), hoping to avoid 
episodes (56.9%) and hoping to get better (42.1%). 
Almost all patients feel extrinsically motivated to adhere 
to the treatment (88.3%); they are motivated by the 
family (75.0%) and health care professionals (34.3%). 
The benefits of immunomodulator medication was 
recognized by 55.3% of participants, and the main benefits 
mentioned were: reduction of episodes of MS (70.8%), 
lighter episodes (38.1%), improvement of incapacity 
(37.2%) and delayed disease progression (30.1%). 
Many patients reported side effects associated with the 
use of immunomodulator medication (60.6%), and the 
most common were: myalgia (50.0%), malaise (48.1%), 
cephalgia (40.3%), fatigue (33.7%), fever (25.0%) and 
hyperemia (25.0%). The difficulty in administering the 
immunomodulator medication was observed in 59.6% of 
participants, and 79.2% reported no difficulties in obtaining 
the medication. Most patients received information about 
the disease (84.6%) and treatment (90.0%). Still, more 
than half of patients reported keeping contact with the 
doctor of the Center on the day of the consultation only 
(59.6%) and many did not return to medical consultations 
(49.5%) (Table II). 
According to the Morisky Medication Adherence 
Scale (MMAS), there was an adherence of 46.0% and 
the main causes for non-adherence were: forgetfulness 
(64.0%) and discomfort in continuing the treatment 
because of its complexity (31.0%) (Figure 1).
There was statistically significant association 
between adherence to treatment with IM and the 
following variables: age under 39, shorter period 
of treatment, shorter period of diagnosis and lower 
Expanded Disability Status Scale scores (EDSS scores). 
Intrinsic motivation, perception of the benefits caused 
by the treatment and extrinsic motivation are protective 
factors for the adherence to medication. Regarding the 
variables related to health care, patients who received 
information about the disease, contacted the doctor by 
the phone and on the day of the consultation and never 
missed their next consultations presented statistical 
significance. The variables age under 39, intrinsic 
motivation, extrinsic motivation, Expanded Disability 
Status Scale score (EDSS score) below 3.5, length 
of treatment, perception of the benefits caused by the 
treatment, contact with the doctor by the phone and on 
the day of the consultation, and never missing their next 
consultations were maintained in the adjusted model with 
statistical significance (Table III).
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DISCUSSION
This study aimed to determine the association 
between factors and adherence to immunomodulator 
treatment in people with multiple sclerosis treated in 
reference centers and has identified an adherence rate of 
46% according to the Morisky Medication Adherence 
Scale (MMAS-8) (Morisky et al., 2008). This value was 
lower than the ones found in studies like a multicenter 
study conducted in Spain health care centers for MS 
patients using the Morisky & Green scale, which found an 
adherence rate of 68% (Fernandez et al., 2012).
It is important to say that some of the differences 
found in the adherence rates of these studies may be 
explained by the variables established to define adherence 
(Gordis, 1989). Choosing a cross-sectional study allowed 
to estimate the proportion of adherence to treatment and 
its associated factors. 
The factors positively associated with adherence 
identified in this study were: younger age, shorter period 
of diagnosis and length of treatment, lower EDSS scores, 
perception of the benefits of the treatment, intrinsic and 
extrinsic motivation. Additionally, receiving information 
about the disease, contacting the doctor more often (by 
phone, for instance) and not missing the next consultations 
have contributed to the adherence to treatment. 
Non-adherence rate was high and it was identified 
that individuals who were not adherent to the treatment 
intentionally discontinued the therapy. Another reason 
was the patient’s forgetfulness, which is an unintentional 
behavior. When it comes to patients with MS, forgetting 
to take the medication may be associated with alterations 
TABLE I - Demographic and socioeconomic characteristics of patients with multiple sclerosis receiving care in Reference Centers. 
Ceará, 2012
Variables n % Mean Standard deviation Median 
Age (years) (N=188)
18-38 100 53.2 38.6 12.5 37.0
39-66 88 45.8
Gender (N=188)
Men 46 24.5
Women 142 75.5
Race/Color (N=185)
White 158 84.0
Pardo 27 14.4
Black 3 1.6
Marital Status (N=188)
Single/Widow(er)/divorced 102 54.3
Married 86 45.7
Education (N=184)
Elementary school/High school 85 45.2
Higher education 99 52.7
Employment (N=171)
Unemployed/retired/disability benefits 107 56.9
Employed 37 19.7
Household income (R$) (N=183)
Up to 2,214.89 134 73.2 5,205.00 6,241.19 3,000.00
Above 2,214.89 49 26.8
Economic status (N=188)
A/B 111 59.0
C/D 77 41.0
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TABLE II - Aspects related to the disease and treatment of patients with multiple sclerosis receiving care in Reference Centers. 
Ceará, 2012
Variables n % Mean Standard deviation Median 
Expanded Disability Status Scale (N=188)
0 – 3.5 123 65.4
4 – 8.0 65 34.6
Period of diagnosis (months) (N=188) 73.9 61.9 60.0
6- 24 36 19.1
More than 24 152 80.9
Length of treatment (months) (N=188) 64.6 48.6 54.5
6 – 24 42 22.3
More than 24 146 77.7
Intrinsic motivation to use the immunomodulator medication (N=188)
Yes 145 77.1
No 43 22.9
Extrinsic motivation to use the immunomodulator medication (N=188)
Yes 166 88.3
No 22 11.7
Perception of the benefits of the immunomodulator medication (N=188)
Yes 104 55.3
No 84 44.7
Side effects (N=188)
Yes 104 60.6
No 84 39.4
Symptoms of side effects (N=104)*
Myalgia 52 50.0
Malaise 50 48.1
Cephalgia 42 40.3
Fatigue 35 33.7
Fever 26 25.0
Hyperemia 26 25.0
Difficulty to administer the immunomodulator medication (N=188)
Yes 76 40.4
No 112 59.6
Difficulty to obtain the immunomodulator medication (N=188)
Yes
39 20.8
No 149 79.2
Received information about the disease? (N=188)
Yes 159 84.6
No 29 15.4
Received information about the treatment? (N=188)
Yes 169 90.0
No 19 10.0
Contacted the doctor (N=188)
By phone and on the day of the consultation 112 59.6
On the day of the consultation only 76 40.0
Missed any consultations (N=188)
Yes 93 49.5
No 95 50.5
*There is more than one answer.
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in the cognitive function (National Multiple Sclerosis 
Society, 2006). 
Changes in the cognitive function are a very 
common symptom of MS that affects 62.4% of patients 
(Fricska-Nagy et al., 2016). Other study has also observed 
that the main cause of non-adherence reported by patients 
with MS was forgetfulness (Devonshire et al., 2011).
It was observed that age (under 39 years old) was 
statistically significant, corroborating with Fernandez 
et al. (2012). It is believed that the disease progression 
hinders adherence by older people. According to the 
World Health Organization (2003), low adherence affects 
all age groups. However, the prevalence of functional and 
cognitive impairment in older patients increases the risk 
of low adherence.
FIGURE 1 - Frequency of positive answers in Morisk 8-item 
scale
TABLE III – Association between adherence and the variables adjusted in the logistic regression model divided into blocks. 
Ceará, 2012
Variables Adherence %
Unadjusted Adjusted
Odds 
Ratio 95% CI P Value
Odds 
Ratio 95% CI P Value
Age (years)
18 – 38 53.0 1.9 1.0-3.5 0.03 2.3 1.2-4.4 0.01
39 – 66 37.5
Gender
Men 37.0
Women 48.6 1.6 0.8-3.4 0.17 1.2 0.6-2.6 0.64
Education
Elementary/High school 41.2
Higher education 48.5 1.3 0.7-2.5 0.32 1.2 0.6-2.6 0.65
Employment
Unemployed 44.9
Employed 46.9 1.1 0.6-2.0 0.78 1.0 0.5-2.0 0.93
Household income (R$)
Up to 2.214,89 44.0
Above 2.214,89 51.0 1.3 0.7-2.7 0.40 1.2 0.5-2.6 0.68
Economic status
A/B 47.7 1.2 0.7-2.3 0.51 1.1 0.5-2.4 0.75
C/D 42.9
Expanded Disability Status Scale
0 – 3.5 52.8 2.3 1.2-4.7 0.01 2.1 1.1-4.1 0.02
4 – 8.0 32.3
Period of diagnosis (months)
6- 24 62.9 2.4 1.0-5.6 0.02 1.9 0.8-4.1 0.12
More than 24 41.4
Length of treatment (months)
6 – 24 59.5 2.0 1.0-4.4 0.04 2.6 1.2-5.8 0.02
More than24 41.8
Intrinsic motivation to use the immunomodulator medication
Yes 55.9 9.6 3.5-32.8 <0.0001 8.5 3.0-23.8 <0.00
No 11.6
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Variables Adherence %
Unadjusted Adjusted
Odds 
Ratio 95% CI P Value
Odds 
Ratio 95% CI P Value
Extrinsic motivation to use the immunomodulator medication
Yes 50.6 10.2 2.3-92.3 0.00 5.9 1.2-28.5 0.03
No 9.1
Perception of the benefits of the immunomodulator medication 
Yes 61.1 4.5 2.3-8.9 < 0.00 4.9 2.5-9.5 < 0.00
No 26.2
Side effects
No 45.9 1.0 0.5-1.9 0.96 1.16 0.6-2.3 0.66
Yes 45.6
Difficulty to administer the immunomodulator medication 
No 50 1.5 0.8-2.9 0.16 1.53 0.7-3.2 0.25
Yes 39.5
Difficulty to obtain the immunomodulator medication 
No 48.6 1.6 0.8-3.4 0.17 1.0 0.5-2.2 0.95
Yes 37.0
Received information about the disease?
Yes 49.7 3.1 1.2-9.1 0.01 2.47 0.6-9.5 0.19
No 24.1
Received information about the treatment?
Yes 47.3 1.9 0.7-6.5 0.19 1.0 0.2-5.1 0.94
No 31.6
Who administers the immunomodulator  medication 
Self-administered 47.8 1.2 0.7-2.3 0.50 0.8 0.4-1.7 0.64
Family/other 42.7
Changes in lifestyle
Yes 46.6 1.1 0.6-1.9 0.86 1.1 0.6-2.3 0.63
No 45.2
Contacted the doctor
By phone and on the day of the consultation 55.3 1.90 1.0-3.6 0.031 1.95 1.0-3.8 0.05
On the day of the consultation only 39.3
Missed any consultations
No 62.4 4.0 2.1-7.6 <0.00 4.3 2.2-8.4 <0.00
Yes 29.5
TABLE III – Association between adherence and the variables adjusted in the logistic regression model divided into blocks. 
Ceará, 2012 (cont.)
The variables related to the disease suggest that 
people with lower EDSS scores and shorter periods of 
diagnosis and length of treatment are more likely to adhere 
to treatment, corroborating the findings by other authors 
(Tremlett et al., 2008; Treadaway et al., 2009; Devonshire 
et al., 2011). Disease progression and the incapacities 
developed hinder adherence because they interfere directly 
with the administration of the injection. In addition, 
cognitive impairment can affect patient’s memory and 
hinder adherence (World Health Organization, 2003; 
Klauer, Zettl, 2008). 
The perception of benefits caused by the use of the 
immunomodulator is strongly associated with adherence. 
This is corroborated by other authors (Treadaway et al., 
2009; Devonshire et al., 2011) and suggests that the main 
cause for adherence to the medication is the hope that it 
will continue to have a positive impact on MS (Turner et 
al., 2007). 
According to the health belief model, one’s decision 
to adopt certain healthy behavior is triggered by the 
perception of the benefits deriving from certain actions 
(Kasser, Kosma, 2012). Factors associated with adherence 
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are focused on the patient and reflect on individual 
expectations (Leite, Vasconcellos, 2003).
This study also showed an association between 
intrinsic motivation and adherence to immunomodulator 
treatment, which is corroborated by other studies (Turner 
et al., 2007; Treadaway et al., 2009; Devonshire et al., 
2011). One’s behavior in certain situations is based on the 
occurrence of intrinsic and extrinsic motivation (Reiss, 
2012). Regarding MS, the intrinsic factor is the patient’s 
motivation to control the disease. The study showed that 
people who received information about the prognosis and 
treatment were more intrinsically motivated to adhere 
to treatment (Apóstolo et al., 2007). Therefore, intrinsic 
motivation is related to the patient’s opportunity to 
maintain or improve his/her health status. Hoping to get 
better and reduce the occurrence of episodes and believing 
that the medication can prevent the disease progression 
were the main causes of motivation reported by the 
participants of this study. 
Considering the extrinsic motivation, it was observed 
that the family support to continue the treatment was 
associated with adherence, a fact that is also highlighted 
by other authors (Klauer, Zettl, 2008; Treadaway et al., 
2009). However, a comprehensive model of adherence to 
treatment should not only have patients follow the therapy. 
It should also keep exogenous influences, especially 
the family support (Klauer, Zettl, 2008). The family 
should accompany the person with multiple sclerosis 
during educational activities as decision-making and the 
difficulties faced by the person can be overcome with 
support from the family and their support network through 
therapeutic groups. There was a positive association 
between adherence and people who received information 
about the disease from health care professionals (Mohr et 
al., 2001; Turner et al., 2007). Information can provide 
patients with the opportunity to participate actively in the 
decisions about his/her treatment. Understanding his/her 
own health status can make them see medication treatment 
as a tool to reduce the harms caused by MS (Saunders et 
al., 2010).
Although immunomodulators are dispensed free 
of charge in all Reference Centers in the country, it did 
not have any influence on the increase in adherence 
to treatment; however, the characteristics of the study 
population should be highlighted as the high education 
and income of participants did not have an impact on the 
increase in the adherence to immunomodulator treatment. 
This fact is also observed in other studies on the adherence 
to treatment of chronic conditions, which is probably 
related to one’s lifestyle rather than being a social influence 
(Dias et al., 2011) 
Another factor that is associated with adherence 
is the way the relationship between the patient and the 
health care professional occurs. In this study, people who 
contacted their doctors more often (by phone, e-mail and 
on the day of the consultation) were significantly more 
adherent to the treatment, a finding that has also been 
observed by Devonshire et al. (2011). The relationship 
between the health care professional and the patient can 
influence the acceptance of a therapy and the adherence 
to it (Tremlett et al., 2008).
Coelho et al. (2005) corroborate higher rates of 
adherence among people who do not miss consultations. 
Missing medical appointments may reflect people’s 
difficulty to recognize the importance of the consultation 
for their health care, leading to the non-adherence to 
treatment. 
A prevalence of white people has been found by 
studies conducted in Southeastern Brazil (Callegaro et 
al., 2001; Fragoso, Pereira, 2007). Different results were 
found in the cities of Recife (Ferreira et al., 2004) and 
Fortaleza (Teixeira, 2011), which presented a prevalence 
of pardos (Portuguese word that refers to mixed-race 
people). This study took into account the self-reported 
skin color. Therefore, its classification was subjective 
(Pena et al., 2011). 
When assessing employment, it could be observed 
that more than half of patients did not have any paid 
jobs, which is also corroborated by Fragosoand Pereira 
(2007). The disease progression and the physical and 
mental impairment reduce the autonomy of people with 
MS. These changes lead to unemployment and early 
retirement (Mitchell et al., 2005). Most patients have 
a higher education level, which is above the national 
educational level - only 20% of Brazilians have a college 
degree (Arelaro, 2005).
The findings of this study can be helpful to explain 
factors associated with adherence among patients with 
MS and warn health care services about the importance 
of the development of individual and collective strategies 
to offer educational support through the provision of 
information about the disease and treatment. Still, it 
suggests interventions that shall reduce the barriers related 
to forgetfulness and it encourages the inclusion of the 
patient’s family in the treatment. 
Finally, the present study suggests, as a solution to 
increase the adherence, the organization of the service: 
the organization of the multidisciplinary team so that the 
nurse can train the patient for the self-administration of 
the immunomodulator through an educational process in 
which the professional can transmit knowledge about the 
disease, treatment and self-administration. By building 
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this knowledge, patients can become involved in self-care 
and have greater autonomy in decision-making regarding 
the adherence to their treatment. Periodic telephone or 
face-to-face counseling should be carried out in order 
to investigate adverse effects and good practices of self-
administration of immunomodulators, reinforcing the 
importance of adherence and encouraging discussion 
on side effects and difficulties of the treatment. Thus, 
providing patients with a space for talking and reflecting 
about their doubts is of utmost importance; additionally, it 
can improve their knowledge about the disease taking into 
consideration the reality and feelings of each one.
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